Third Raise, First Narrowing of the US Obesity Gap, and a Medicare Bridge That Expires in 2027

Results vs. Consensus

Novo Nordisk reported before the European open on 4 November 2026 and hosted its call at 13:00 CET, 7:00 AM ET, ahead of the US open. For the third consecutive quarter the results have to be read on two bases, and for the first time this year there is no sales distortion at all in either period. There was no 340B provision reversal in either the third quarter of 2026 or the third quarter of 2025, so reported and adjusted sales are the same number in both periods. Reported operating profit carries DKK 8.7bn of non-cash impairments: DKK 4.6bn on ziltivekimab following the termination of the HERMES and ATHENA trials, and DKK 4.1bn on the right-sizing of the manufacturing network. The adjusted basis strips those and is the one management guides against.

It does not strip everything that matters. The single most important feature of this scorecard is that Novo's adjusted operating profit definition excludes major impairments, major legal matters and 340B reversals, but not major restructuring costs, while its adjusted net profit definition does exclude them. The third quarter of 2025 carried roughly DKK 9bn of company-wide transformation cost. That charge therefore sits inside the operating-profit comparative and outside the earnings comparative, which is how a quarter produces 27% operating-profit growth and a 12% earnings decline simultaneously.

Q3 2026 Scorecard (adjusted basis, DKK)

A note on the consensus set. The three lines with a polled figure are the three the company circulates to contributing analysts, and they are the lines management is judged on. A second set is published in dollars per ADR, which beat by roughly a tenth on earnings and 7% on revenue. We do not carry it in the scorecard, because the actual it is compared against moves with the exchange rate chosen: adjusted diluted EPS of DKK 5.79 is $0.90 at the nine-month average rate of 6.43 kroner to the dollar and $0.86 at the company's stated 29 October spot of 6.71, which is the entire difference between the $0.87 and $0.89 actuals that circulated on the day. No DKK-denominated earnings poll was available, so the earnings line is marked as having no comparable consensus rather than being compared against a number struck on a different basis. A cross-reference set put adjusted sales at DKK 73.6bn and adjusted operating profit at DKK 28.6bn, which would make the beats 7.6% and 10.9%. The direction and the order of magnitude agree across both.

Year-over-Year Comparison

Three things in that table deserve to be read together. The adjusted cost of goods sold line fell 21% in kroner on 6% sales growth, which drove the 600 basis points of gross-margin expansion. Sales and distribution fell 9% at constant currency, a third consecutive decline after 13% in each of the first two quarters. And adjusted operating profit rose 34% in kroner while adjusted earnings per ADR fell 12%. Only one of those three is a trading result.

The reason is the prior-year base. The third quarter of 2025 was the quarter Novo announced and booked its company-wide transformation, at roughly DKK 9bn, of which DKK 8,090M is classified as major restructuring cost. The cost-of-goods ratio tells you where most of it landed: 23.9% of sales in the third quarter of 2025 against 17.3% of adjusted sales in the second quarter of 2025, a 6.6 point step that implies roughly DKK 4.9bn of the charge sat in the cost line. That is a reconstruction rather than a disclosure, and we flag it as such, but it means the 600 basis points of gross-margin gain compares against a base that was artificially depressed. Adding that DKK 4.9bn back puts the third quarter of 2025 near an 82.7% gross margin, against 82.1% this quarter. The clean, disclosed comparison points the same way: nine-month adjusted gross margin of 80.3% against 80.8%, down 50 basis points.

Sequential Comparison

Sales were essentially flat sequentially, up 0.9%, which after a second quarter that grew 12.0% off a depressed first quarter is the first evidence of a settled run rate. The gross margin recovered 390 basis points because the DKK 3bn manufacturing right-sizing charge that sat in the second quarter's cost line did not repeat, and because this quarter's DKK 4,061M manufacturing impairment is excluded from the adjusted figures rather than buried in them.

The research and development line is the one to watch. Adjusted research spend rose 33.1% sequentially and the ratio moved 470 basis points, from 14.6% of sales to 19.3%. Roughly DKK 1.7bn of that is the one-time cost tied to closing out ziltivekimab, with the balance of the stated DKK 3.5bn of one-time items sitting in other operating expenses, which swung from a DKK 234M loss to a DKK 1,788M loss on non-core manufacturing contracts. Strip the research-line portion and the ratio is roughly 17.1% of sales, still 250 basis points above the first half. The split is our reconstruction, not a disclosure, but either version says the same thing: the research step-up promised in May and deferred in August has now arrived.

Sales and distribution did not. The ratio was 19.0% against 19.1% in the second quarter and 18.2% for the first half. In May management guided the full-year SG&A ratio, sales and distribution plus administration, to the "low 20s", and has not repeated the number since. On that basis the ratio was 20.5% this quarter and 20.1% for the nine months, so the guide is being met rather than missed, and it does not point to a large promotional step-up still to come.

Nine-Month View

Nine months in, the operating line is growing and the earnings line is not. Adjusted sales up 2% at constant currency, adjusted operating profit up 8%, adjusted earnings per ADR down 3%. The gap between the second and third of those is the DKK 8,090M of 2025 restructuring that the operating comparative carries and the earnings comparative does not, plus about three points of currency, since in kroner the operating line grew 5%. Anyone building a 2026 earnings estimate by applying the operating-profit guide to the 2025 earnings base will overstate it by roughly DKK 2 per share, and we set out the corrected build in the Model Update section below.

Quality of Beat/Miss

• Revenue: The cleanest revenue quarter Novo has printed in our coverage. Growth of 4% at constant currency is volume-led in both operating units, and for the first time there is no gross-to-net distortion in either direction: the company states that US gross-to-net adjustments were "neutral to growth in the quarter, with similar positive impacts in Q3 2025 and Q3 2026." Compare that with the second quarter, where roughly three of seven growth points were a prior-period rebate true-up, and the first quarter, where two-fifths of the pill line was channel fill. There is no acquisition contribution. The one qualification is that International Operations booked a one-off prior-period adjustment on Ozempic, which the company says was offset by the Canadian loss-of-exclusivity impact, so the two net out within the region.
• Margins: Worse than the headline, better than the nine-month trend. The reported 600 basis points of gross-margin gain compares against a cost line we reconstruct as carrying roughly DKK 4.9bn of 2025 transformation charge; on a clean basis the gross margin is down roughly 60 basis points year on year, consistent with the 50 basis point decline in the disclosed nine-month comparison. Below the gross line the operating leverage is real and unchanged: sales and distribution down 9% at constant currency on 4% higher sales, administrative costs down 34%. The underlying operating margin gain of roughly 90 basis points is the honest number.
• EPS: Adjusted diluted EPS of DKK 5.79 fell 12% against operating-profit growth of 27% at constant currency, and almost all of that spread is definitional rather than operational. Financial items swung to a DKK 1,577M loss from a DKK 1,835M gain, a DKK 3.4bn deterioration that is itself worth roughly DKK 0.60 per share after tax and is the one genuine below-the-line drag. The effective tax rate was near-flat at 21.9% against 21.6%, and the diluted share count fell 0.5% to 4,422.9 million. DKK 10.0bn of buybacks against DKK 51.9bn of dividends over nine months is not a per-share lever.

Segment Performance

Adjusted Sales by Geography

Both operating units grew for a second consecutive quarter, which the chief executive put first in his prepared remarks. It is the first quarter in which the US growth is clean: the second quarter's +4% carried roughly five points of prior-period rebate true-up, so ex that item US Operations was still shrinking, while this quarter the company states gross-to-net was neutral to growth. The composition is unflattering: International Operations contributed 93% of group growth, and inside it a single region, EUCAN, contributed 100%. Region China inverted from +13% at constant currency to -5%, and APAC deteriorated from -6% to -7%. The group grew because EUCAN grew 18% after 17% in the second quarter and because the US stopped shrinking, not because the geographic base broadened.

Adjusted Sales by Therapy Area

Diabetes went back into reverse. After a second quarter in which the segment grew 3% at constant currency on a DKK 50.4bn base, it fell 5% on a DKK 47.5bn base, and total GLP-1 diabetes swung from +2% to -7%. Roughly half of that reversal is the second quarter's rebate true-ups not repeating: we flagged in August that stripping roughly DKK 2bn of Ozempic and insulin true-ups put the segment close to flat rather than up 3%. The move from close to flat to a 5% decline, in a quarter where the company says US gross-to-net was neutral to growth, is a genuine deterioration. Obesity compensated, growing 22% on a base that has risen from DKK 23.2bn to DKK 26.1bn in a single quarter, which is why the group still grew 3% in the combined segment.

Inside obesity, the mix has changed completely in nine months. Wegovy injectable is now flat to down, at 0% in kroner and -2% at constant currency, while the pill at DKK 5,394M is 21% of total obesity sales. The pill grew 67.6% sequentially from DKK 3,218M, which is a figure worth stating precisely because two wire reports put the sequential gain at 53%; the company's own appendices give nine-month pill sales of DKK 10,868M and third-quarter sales of DKK 5,394M, which with the sourced first-quarter figure of DKK 2,256M leaves DKK 3,218M for the second quarter. The arithmetic is the release's own.

Obesity Versus Its Own Market

This is the table that set the rating in May, held it in August, and is the reason this quarter is a genuine decision rather than a formality. It is the company's own, sourced to IQVIA moving annual totals at August 2026, against the May 2026 vintage carried in the prior report.

The US line moved favourably on both legs for the first time since we initiated. Novo accelerated from 4% to 20% while the branded market's volume growth decelerated from 87% to 71%, taking the gap from 83 points to 51 and the growth ratio from 0.05 to 0.28. In May and again in August we named the narrowing of this specific gap as one of two conditions for moving toward Outperform. On the face of the table, it has been met.

Two other regions went the other way, and one of them matters. Emerging Markets, which in August was the only geography growing at a rate within hailing distance of its category at 45% against a 55% market, collapsed to 4% against a 50% market. APAC deteriorated on both legs, from -9% against a 53% market to -22% against a 30% market. International obesity as a whole decelerated from 37% to 24% even as its market decelerated from 71% to 68%, so the international ratio worsened while the US ratio improved. The company's geographic engine of growth and its geographic engine of share recovery are now different places.

GLP-1 Diabetes Versus Its Own Market

The under-growth pattern that obesity partially repaired, diabetes made worse. US GLP-1 diabetes swung from +3% to -10% against a market still expanding volumes 12%, and the international franchise fell 2% against a market growing 37%. Emerging Markets is the extreme case: an 18% decline against an 82% volume expansion. Only EUCAN participates, at 13% against 24%. On the two therapy areas combined, the share story has not turned; it has rotated.

US Operations

US adjusted sales of DKK 41,880M grew 1% at constant currency, with obesity up 20%, GLP-1 diabetes down 10%, insulin down 13% and blood and endocrine disorders up 27%. Total US GLP-1 sales were, in the company's words, "stable at 0% growth at CER". Inside obesity, Wegovy injectable fell 13% at constant currency to DKK 11,066M, against -22% in the second quarter, and the pill contributed DKK 4,178M. Combined Wegovy product sales rose 21% at constant currency.

The narrowing of the injectable decline is the quarter's most under-discussed number. Sales rose 14.8% sequentially, from DKK 9,636M to DKK 11,066M, against volumes that management said grew around 10% sequentially. That implies realised price per unit rose roughly 4% quarter on quarter, the first sequential improvement in the two quarters for which the company has disclosed both a volume direction and a sales level. The self-pay share of US injectable Wegovy prescriptions held at around 35%, unchanged from the second quarter and up from around 10% to 15% a year earlier. The mix shift that drove the 22% decline has plateaued, and what replaced it is a reimbursed Medicare channel.

"Relative to Bridge, latest weekly data, we are seeing about 60,000 TRXs across injectable and oral in terms of Bridge. The sequential growth of 20% in the quarter is largely, but not exclusively, Bridge volume." — Jamey Millar, EVP US Operations

Against a franchise running roughly 592,000 US Wegovy prescriptions a week in the quarter, 3.6 million pill and 4.1 million injectable over thirteen weeks, 60,000 weekly Bridge prescriptions is roughly a tenth of current volume. Medicare Part D coverage for obesity medicines became available through Bridge on 1 July 2026, so the programme contributed nothing to the comparative base and ramped from zero inside the quarter. It is a demonstration project with an end date in 2027.

Assessment: The US franchise has stopped deteriorating and the mechanism is clear: a reimbursed channel opened on 1 July and is now roughly a tenth of weekly volume, carrying better realised pricing than the self-pay channel it supplements. That is a real improvement and it is why the obesity gap narrowed. It is also a dated improvement. The head of US Operations said, twice, that the whole category is relatively flat without Bridge. The question the quarter answers is whether US obesity can grow; the question it leaves open is whether it can grow on commercial and self-pay demand alone, and management's answer was that the quarter's growth was "largely, but not exclusively" Bridge.

International Operations

International adjusted sales of DKK 37,315M grew 8% at constant currency, led by EUCAN at 18% and Emerging Markets at 6%, against declines of 7% in APAC and 5% in Region China. Obesity grew 24% with Wegovy injectable up 16% and the pill contributing DKK 1,216M across the UK, UAE and Germany. Combined Wegovy product sales grew 31% at constant currency. GLP-1 diabetes fell 2%, with Ozempic up 8% on EUCAN volumes but Victoza and Rybelsus both declining, and with the Canadian loss of exclusivity now visible in realised prices against broadly stable volumes.

The pill rollout accelerated against its own Capital Markets Day plan. The product is now in eight markets globally, having added Mexico, Spain, France and Poland after the quarter closed, and management brought forward its target of more than 20 markets from the end of 2027 to the first half of 2027. Germany sold approximately 100,000 packs in six weeks, mainly to GLP-1-naive patients. The UK, the launch that produced August's best datapoint, has begun to normalise.

"On the U.K. we are still very pleased, and with 90% market share despite a competitor launch, of course, is very strong. In terms of how we fare versus what we shared at the Capital Markets Day, we back then talked about 65,000 packs weekly sales. Now we are probably around 60. So despite a competitor launch, super strong, and also with the seasonality at the moment being a bit low, we move into November, December, that is typically peak, where the online providers also invest heavily. I think what you should also take note of, which we really are keenly focusing on, is of course that this is not cannibalizing our injectable business." — Emil Kongshøj Larsen, EVP International Operations

Novo's international GLP-1 volume share was disclosed at 54%, against approximately 58% on the same all-GLP-1 basis in August and approximately 55% injectable-only in May. On the one basis that has been held constant for two quarters, international share fell four points.

Assessment: The international pill rollout is executing ahead of plan and the UK evidence on cannibalisation is holding, with Novo's overall UK obesity share still more than ten points above pre-launch. Those are the two things that had to be true for the oral thesis, and both are. The offsets are that the UK run rate has turned down from 65,000 to roughly 60,000 packs a week against a competitor launch, that international obesity growth decelerated 13 points while its market decelerated only three, and that the international GLP-1 volume share fell four points on a consistent basis. International remains the half of the business that grows. It is no longer the half that is also taking share.

Diabetes

Diabetes adjusted sales of DKK 47,545M fell 5% at constant currency, with US diabetes down 11% and international diabetes up 2%. Ozempic fell 5% globally, giving back the second quarter's 5% gain, with US Ozempic down 11% on lower volumes and wholesaler inventory movements and international Ozempic up 8% on EUCAN volumes plus a one-off prior-period adjustment offset by the Canadian loss of exclusivity. Ozempic pill, the rebranded Rybelsus, fell 10% globally but grew 5% in the US, where weekly new-to-brand prescriptions are running roughly double pre-launch levels under the old brand.

"Turning to diabetes, the transition from Rybelsus to Ozempic pill is now complete, with new patients starting directly on the Ozempic brand. Since launch, weekly new-to-brand prescriptions for the oral franchise have more than doubled... Importantly, more than 60% of Ozempic pill new-to-brand prescriptions are from people who are new to GLP-1 treatment." — Jamey Millar, EVP US Operations

Insulin grew 2% globally, with International Operations up 8% on Emerging Markets volumes and US insulin down 13% on share loss, a declining market and channel mix. On price, management reiterated an annual framework rather than a quarterly one: roughly 10% to 15% price erosion on Ozempic and 30% to 35% on Wegovy. Ozempic ran significantly better than its range in the quarter, Wegovy ran within its own, and management would revise neither.

Assessment: The rebranding is working on the leading indicator and not yet on revenue, which is the correct sequence but makes the diabetes line a 2027 story rather than a 2026 one. The more consequential point is that the second quarter's +3% was flattered by prior-period rebate true-ups and this quarter's -5% was not, so the underlying trajectory has moved from roughly flat to down 5%. Against a US GLP-1 diabetes market still growing volumes 12% and an international market growing 37%, a declining franchise is continued share loss in the larger half of the company.

Blood & Endocrine Disorders

The segment, renamed from Rare disease, grew 15% at constant currency to DKK 5,504M, with endocrine disorders up 43% on Norditropin and Sogroya volumes and blood disorders up 3%. US sales grew 27%. Segment operating profit of DKK 1,437M at a 26.1% margin compares with a DKK 540M loss a year ago, and unlike the second quarter the reported segment line is informative this time, because the quarter's impairments are named and attributable.

The pipeline news here is the most concrete of the quarter. Frehemgo, the brand name for denecimig in haemophilia A, received a positive CHMP opinion on 17 September with first European launches planned around the turn of the year. Sogroya received a positive CHMP opinion in the EU and approval in China for non-replacement indications. Etavopivat, whose HIBISCUS phase 3 trial met both co-primary endpoints in April, still has US and EU submissions guided to the fourth quarter. Against that, the US review of the denecimig biologics licence application has been extended over manufacturing facility remediation, pushing the planned US launch into the first half of 2027. The company states the FDA has identified no deficiencies in the clinical efficacy or safety data.

Assessment: Still 7% of sales, still immaterial to 2026, and still the cleanest part of the story. Two positive CHMP opinions and an approval in China in one quarter is a better hit rate than the rest of the pipeline managed. The denecimig delay is a manufacturing problem rather than a drug problem, which is the better of the two kinds, but it is the second time this year a Novo manufacturing issue has moved a date and it lands while the company is simultaneously right-sizing that network at a DKK 4.1bn impairment.

Commercial KPIs

Key Topics & Management Commentary

Overall Management Tone: Confident on the commercial story and unusually forthcoming on the parts that are not working, which is a different posture from both the uniform confidence of the first-quarter call and the careful defensiveness of the second. The most striking feature was that the two most damaging admissions of the quarter, that the US category is relatively flat without a government demonstration programme and that the UK pill run rate has turned down, came from management in direct answers rather than being extracted. Tone turned noticeably vaguer on 2027, where a departing chief financial officer declined to guide and the chief executive substituted a list of three positives and three negatives for a number.

1. The Third Guidance Raise, and Where the Floor Now Sits

Full-year adjusted sales growth and adjusted operating profit growth both move to -2% to +2% at constant currency from -6% to 0%, which lifts the floor four points, the ceiling two, and narrows the band from six points to four. Free cash flow guidance rose DKK 15bn to DKK 60-70bn and capital expenditure guidance fell DKK 5bn to around DKK 50bn, with the company stating that capital expenditure is expected to keep declining in the coming years.

"For the first nine months of 2026, Novo has delivered better-than-expected sales and operating profits. As a result, we have raised our guidance again." — Karsten Munk Knudsen, CFO

Set against the February opening guide of -13% to -5%, the floor has moved 11 points and the ceiling seven across three revisions, each delivered on banked results rather than expected ones. The shape matters as much as the level. May was a one-point parallel shift that left the band eight points wide. August and November each lifted the floor by more than the ceiling and narrowed the band, to six points and then four. That is de-risking rather than re-forecasting, and it is now a two-revision pattern.

Assessment: Three raises in nine months on delivered results is the behaviour of a management team rebuilding a forecasting reputation, and it has largely succeeded: the credibility discount that applied in May is no longer defensible. The limit of what it buys is that every raise so far has upgraded a period already in the bank. The company's best case for 2026 is still only 2% growth, and the February guide, which is the one that spans the January list-price reset, will be delivered by someone who has not given one before.

2. Both Operating Units in Growth, and What Carried Them There

US Operations grew 1% at constant currency and International Operations 8%, the second consecutive quarter with both positive and the first in which the US figure carries no prior-period rebate benefit. Behind it the company reported adding 1.3 million patients in the quarter after 1.2 million in the second, with obesity adding 0.7 million and diabetes swinging from losing 0.8 million patients in the first quarter to adding about one million across the last two.

"The quarterly development clearly shows that we are at the growth recovery phase, and that is progressing well. Following adjusted sales decline of 2% in the fourth quarter of 2025 and 4% in the first quarter of 2026, we returned to 7% and 4% growth in the second and the third quarter respectively." — Mike Doustdar, President and CEO

The sequence quoted is accurate and slightly flatters the trend, because the 7% in the second quarter included roughly three points of prior-period rebate true-up that did not repeat. On a clean basis the two quarters are closer to 4% each, which is a steadier recovery than the quoted numbers suggest rather than a weaker one.

Assessment: The patient-count series is the most useful disclosure Novo added this year, because it separates demand from price in a company where the two have been moving in opposite directions for eighteen months. Diabetes going from losing 800,000 patients in the first quarter to adding a million over the next two is a bigger change than the 5% revenue decline in that segment conveys. The caution is that patient volume at a declining realised price is precisely the condition that has produced two years of revenue disappointment, and nothing in the guidance says that changes in 2027.

3. Wegovy Pill: The Quarter It Became a Global Franchise

Pill sales of DKK 5,394M split DKK 4,178M in the US and DKK 1,216M internationally, up 67.6% sequentially and beating the polled figure by 16.8% after narrowly missing it in the second quarter. Cumulative US prescriptions exceeded eight million since the 5 January launch. The product is in eight markets and the target of more than 20 was pulled forward from the end of 2027 to the first half.

"Since launch, we have seen more than eight million cumulative prescriptions, which remains the strongest U.S. pharma launch by volume in over a decade, outside of vaccines. We see a long runway for the pill in the U.S. with current and incoming initiatives expected to drive more uptake into the new year." — Jamey Millar, EVP US Operations

The pricing picture improved. Implied realised revenue per US prescription rose to approximately DKK 1,161, roughly $173, from approximately DKK 1,083 in the second quarter, a sequential gain of roughly 7% on rounded script counts, against a self-pay list of $149 to $299 by dose. More than 30% of weekly US prescriptions are now for the 9 mg and 25 mg doses, and the reimbursed Bridge channel adds volume at a different price point than cash-pay. The acceleration in the rollout came from supply and regulatory execution rather than demand.

"On the acceleration, it is really back to, of course, manufacturing stepping up, producing above what the lines are expected to be able to deliver. I've been visiting myself to cheer on the teams, and they're really doing a great job working 24/7. Another aspect is regulatory. We've actually taken some learnings from how we also rolled out Wegovy injectable very quickly, working with multi-country packs, et cetera." — Emil Kongshøj Larsen, EVP International Operations

Assessment: This remains the best asset in the business and the pricing data is the first evidence that the oral franchise can be monetised rather than merely populated. The counterweight arrived outside the call, where the chief executive told reporters the pill's prescription curve had flattened in recent weeks, attributing it to seasonality and hoping for a pick-up around the New Year. Combine that with the UK moving from 65,000 to roughly 60,000 packs a week and the honest read is a franchise that is still scaling geographically while its two proof markets decelerate.

4. The Medicare Bridge Programme, and the Category That Is Flat Without It

Medicare Part D coverage for obesity medicines became available through the Bridge pilot programme on 1 July 2026, covering a majority of beneficiaries. It is running at approximately 60,000 weekly prescriptions across injectable and oral, roughly a tenth of Novo's US Wegovy franchise volume, and it is the main driver of the 20% sequential growth in US pill volumes.

"Without the Bridge contribution, there is less growth than the 20% sequential growth that we talked about. Bridge is definitely creating an inflection in the category, and without Bridge, the AOM category, not just Novo, but the category, looks relatively flat in the May to October timeframe, reflecting the seasonality." — Jamey Millar, EVP US Operations

Management's framing is that Bridge is creating an inflection and that the residual flatness is seasonal: the wellness period starts in the fourth quarter and peaks with New Year resolutions. Both readings are available from the same data. What is not in dispute is that the programme is a demonstration project scheduled to end at the end of 2027, that its extension is a political decision, and that the chief executive lists its annualisation as a 2027 positive.

"It is difficult to predict what the political environment is going to look like at the end of 2027... I think as more and more seniors enjoy this coverage for GLP-1s for weight loss, that will put pressure politically on continuation of the program. The benefit of this demonstration project is to document eligibility, inclusion, cost, and outcomes so that they can make a determination." — Jamey Millar, EVP US Operations

Assessment: This is the most important disclosure of the quarter and it inverts the headline. The condition we set for an upgrade was that US obesity revenue growth reaccelerate while the market's volume growth decelerated toward it. Both happened. But the reacceleration is substantially a government reimbursement programme with a 2027 expiry, layered onto a commercial and self-pay category that management says is relatively flat. A share gap closed by a demonstration project is not the same evidence as a share gap closed by competitive demand, and the Outperform case needs the second.

5. US Injectable Wegovy: The Decline Halves

US Wegovy injectable fell 13% at constant currency against a 22% decline in the second quarter, with sales up 14.8% sequentially on volumes up roughly 10%. Self-pay held at around 35% of prescriptions. Combined US Wegovy product sales, injectable plus oral, grew 21% at constant currency, and total US GLP-1 sales were flat.

Management's price framework for the franchise was repeated without revision: the quarter ran "a little on the high end" of the 30% to 35% range, with "that or a little better" expected from here.

"On the Wegovy side, we've again seen 30%, 35% in the quarter, again, with the variability, a little on the high end, but we expect that or a little better moving forward. Just to clean up maybe one question that was asked before that I missed and has been answered previously. Because of the Ozempic trend, MFP pricing, we don't expect to have an incremental negative consequence, because that's been the trajectory we've been on." — Jamey Millar, EVP US Operations

That last sentence is a claim that the Medicare maximum fair price is already inside the realised number, and it was offered unprompted, as a correction to an answer management had skipped earlier in the call.

Assessment: A 13% decline is still a decline, but the sequential price improvement of roughly 4% per unit is the first reversal we can measure of the mechanism that drove the bear case all year, and it comes from channel mix improving rather than from list price. The claim that the Medicare negotiated price carries no incremental drag is important if true and entirely unquantified. It should be read alongside the January list-price reset, which cuts Wegovy's wholesale acquisition cost by roughly half on the same date and remains unquantified for a third consecutive quarter.

6. Wegovy HD, Seven Months In

Wegovy HD, the 7.2 mg dose launched nationwide in the US on 7 April, runs at approximately 20,000 prescriptions a week, or about 5% of total Wegovy injectable volume, unchanged from the second quarter. Management disclosed the composition for the first time.

"In terms of Wegovy HD, the 7.2 mg, as you stated, about 20,000 prescriptions a week, 5% of total volume. If you look into the injectable business, both Lilly's and ours, about 15% of the TRxs are in the highest dose. There is still opportunity to move Wegovy HD further. 80%, your specific question, 80% of Wegovy HD is titration from 2.4 mg. Those 20,000 scripts a week are scripts that otherwise would have been lost to the Wegovy franchise." — Jamey Millar, EVP US Operations

Internationally the pattern is similar and earlier: in the UK, launched in early June, around 5% of injectable patients have started on the high dose, with more than 30 launches promised across International Operations by year end and the single-dose pen in 17 EU markets by the end of October, according to the company announcement.

Assessment: This closes the question we have carried since May. The thesis pillar said that restoring efficacy parity at 20.7% mean weight loss would close the gap that drove two years of share loss. Seven months after launch, HD is 5% of injectable volume against a category in which 15% of prescriptions sit at the top dose, 80% of it is existing Wegovy patients titrating rather than competitive switching, and the franchise's new-to-brand share has fallen for a second consecutive disclosure. Management's own framing, that these are scripts "that otherwise would have been lost", describes retention rather than recapture. The pillar as written is broken, and the US obesity reacceleration came from the pill and Bridge instead.

7. Ozempic Pill and the Diabetes Rebrand

Ozempic pill, launched nationwide in the US on 4 May as the rebranded Rybelsus, is running weekly new-to-brand prescriptions roughly double pre-launch levels, with more than 60% of those coming from patients new to GLP-1 treatment. US Ozempic pill sales grew 5% at constant currency while the global line fell 10%. An FDA decision on the 25 mg dose is expected in the fourth quarter.

Management was asked whether the rebrand should be exported and declined to commit, prioritising the Ozempic 2.0 mg rollout instead, which is in 13 International markets year to date with 20 planned by year end.

"At the moment, our focus is the 2.0 launches. We've come late to that in IO, launched in 13 markets year to date, 20 by the end of the year... That will already reinforce the Ozempic brand at a moment where, for your building blocks for next year, we are facing increasing competition, particularly in reimbursed markets across IO from a well-known competitor to you all." — Emil Kongshøj Larsen, EVP International Operations

Assessment: A doubling of new-to-brand prescriptions with 60% drawn from GLP-1-naive patients is category expansion, and it is the same playbook that worked for the obesity pill. It has not yet produced revenue, because the installed Rybelsus base is larger than the new-patient flow and is declining at a faster rate. The more revealing line is the acknowledgement that International reimbursed markets face intensifying competition from the category leader, which is a forward-looking admission that the one geography currently carrying group growth gets harder next year.

8. The Cost Base: Savings Delivered, Now Being Spent

Sales and distribution costs fell 9% at constant currency, a third consecutive decline after 13% in each of the first two quarters, with the company stating underlying spend was stable year on year, and the ratio printed 19.0% of sales. Administrative costs fell 34%. Adjusted research costs were down 1% at constant currency but up underlying once the 2025 transformation costs and the 2026 ziltivekimab closure cost are excluded. Headcount is stated as more than 66,500, against roughly 66,700 in August, so the twelve-month reduction of almost 12,000 has stopped.

The guidance language is explicit about where the savings now go.

"The expectation for adjusted operating profit growth primarily reflects the improved sales outlook, combined with targeted investments in current and future growth opportunities within R&D and Commercial, including launch preparations for CagriSema in the US, partly funded by reinvestment of savings from the company-wide transformation in 2025 as well as further optimisation initiatives and disciplined resource allocation." — Company announcement, Outlook

The research ratio moved 470 basis points sequentially, or roughly 250 basis points excluding the one-time cost, which is the step-up promised in May and absent in August finally appearing. The sales and distribution ratio did not move, and with administration added the SG&A ratio was 20.5%, inside the "low 20s" full-year guide given in May.

Assessment: The cost reset was the one pillar that strengthened in August and it has held. What changed is the use of the money: the transformation is now funding a launch rather than a margin. That is the right allocation with CagriSema approaching and it is also why the implied fourth quarter is as weak as it is. The loose end is the size of the commercial step-up. The nine-month SG&A ratio of 20.1% already sits in the "low 20s" range guided in May, so that guide does not require a large fourth-quarter promotional push, and the outlook does not split the launch investment between commercial and research.

9. The Reported Versus Adjusted Problem, Third Quarter Running

Reported operating profit fell 9% at constant currency while adjusted operating profit rose 27%, a 36-point spread created by DKK 8.7bn of non-cash impairments. Reported net profit fell 16% and reported diluted EPS 16%, while adjusted net profit fell 12%. For the nine months the distortion runs the other way: reported sales up 13% at constant currency against adjusted up 2%, because of the DKK 26.8bn 340B reversal booked in the first quarter.

The nine-month impairment total is DKK 15.0bn: DKK 4.6bn on ziltivekimab, DKK 4.0bn on monlunabant, DKK 2.3bn on other pipeline assets and DKK 4.1bn on manufacturing network right-sizing. The 340B reversal has no cash effect.

Assessment: Three consecutive quarters in which the reported figures are unusable, pointing in different directions in different periods, is now a structural feature of this investment case rather than an accident. The practical consequence is that anyone screening on trailing reported numbers sees nine-month sales up 13% at a company guiding to flat, and anyone screening on trailing reported earnings sees a 16% quarterly decline at a company whose operating profit rose. The subtler trap is inside the adjusted figures themselves, where the operating-profit and net-profit definitions treat the 2025 restructuring charge differently. That asymmetry is disclosed, in two separate appendices, and it is the single easiest way to build a wrong 2026 estimate.

10. CagriSema: The Endpoint Miss Repaired, the Launch Brought Forward

The specific pipeline break of the second quarter was CagriSema failing the HbA1c half of REIMAGINE 4's dual primary endpoint against tirzepatide. This quarter the company completed REIMAGINE 5, a head-to-head trial of CagriSema 1.0/1.0 mg against tirzepatide 5 mg in more than 1,000 patients with type 2 diabetes, which delivered superior weight loss of 12.4% against 9.1% and non-inferior HbA1c reduction of around 1.7 percentage points. REDEFINE 9 showed 21% weight loss at the same low dose at week 68 in obesity. The US obesity decision is still expected by the end of 2026 and the launch is now framed as early 2027.

"This is a very relevant comparison, as around 50% of global patients on tirzepatide are on the five milligram dose or less, thus doing a more or less like real-world evidence study. At one milligram of each component, CagriSema demonstrated superior weight loss of 12.4% compared with 9.1% for tirzepatide, while delivering on par non-inferior HbA1c reduction of around 1.7 percentage points." — Martin Holst Lange, EVP R&D and CSO

Management also began to sketch a commercial frame, the absence of which we flagged as an omission in August, though it stopped well short of a launch plan.

"Increasingly, as more competitors come into the category, having a portfolio of singlets, doublets, triplets over time is going to be really important from a competitive standpoint... as the information data emerges on CagriSema, there is a nice profile that is emerging in terms of the efficacy of the product, even at lower doses, as Martin described, and the patient population, perimenopausal women, where we recently announced the 25% weight loss seen in the study." — Jamey Millar, EVP US Operations

Assessment: This is the quarter's most genuine repair. The comparator choice is defensible rather than cherry-picked, because half of tirzepatide patients sit at 5 mg or below, and winning on weight loss while matching on glycaemic control at the low dose is the profile the diabetes submission needed. The commercial frame remains thin: a low-dose and women's-health positioning is a segmentation hypothesis, not pricing, and the launch now sits inside the same quarter as the list-price reset. No pricing, access or cannibalisation assumption for CagriSema has been published.

11. Ziltivekimab Trials Closed, Denecimig Delayed

Following a Data Monitoring Committee recommendation, Novo discontinued study treatment and closed the HERMES trial of ziltivekimab in HFpEF, and ATHENA is completing as planned with the last patient through treatment. Both read out in the first half of 2027. The quarter carried a DKK 4.6bn non-cash impairment on the asset. Separately, the US review of the denecimig biologics licence application remains open over manufacturing facility remediation, with no clinical deficiencies identified, pushing the planned US launch to the first half of 2027. The ARTEMIS trial in acute myocardial infarction still reads out in the first half of 2027.

Set against the closures, the quarter initiated five phase 3 trials on zenagamtide alone, in obesity, diabetes, Japanese patients and cardiovascular outcomes, advanced oral amylin 355 into phase 2, filed CagriSema and oral semaglutide 25 mg in China, and had run seven first-human-dose studies by the end of October against a pipeline of ten ongoing phase 3 programmes.

Assessment: Ziltivekimab is now finished as an investment consideration rather than impaired, which is cleaner than carrying it at option value, and the remaining readouts are free options on a mechanism that has failed its primary endpoint twice. The denecimig delay is the more annoying item because it is self-inflicted and because it arrives in the same quarter the company impaired DKK 4.1bn of manufacturing capacity. What the quarter does show is breadth: five phase 3 starts on a single molecule is the activity level the Capital Markets Day promised, delivered one quarter later.

12. A CFO Transition Into the February Guide

Karsten Munk Knudsen leaves after 27 years, nine of them as chief financial officer, remaining until the end of December 2026. Luigi La Corte joins from Galderma, where he is chief financial officer, having previously held the same role at Recordati from 2019 to 2025 and senior finance roles at GSK, AstraZeneca, PepsiCo and Procter & Gamble.

"As Mike mentioned, this will be my last conference call as CFO at Novo... I leave with great confidence in our strategy, our strong financial foundation, and above all, the people who drive Novo forward every day." — Karsten Munk Knudsen, CFO

The departure is described as mutually agreed and the company says it has run a rigorous selection process. The timing is what matters: the handover completes at the end of December, and the next guidance event is 3 February 2027, which is the first guide to span the 1 January list-price reset and the first 2027 outlook of any kind.

Assessment: There is nothing in the disclosure to suggest this is anything other than it appears, and the successor's profile is appropriate. The consequence for the investment case is procedural rather than substantive: the most consequential guidance Novo will give in three years will be delivered by someone four weeks into the role, on a pricing reset his predecessor declined to quantify three times. That is a reason to discount the February guide's precision, not its honesty.

13. The Rebrand, and the 2030 Frame It Sits Inside

The company now presents itself as Novo rather than Novo Nordisk throughout its own announcement, having introduced what the chief executive called "a new strategy, culture, and a brand" during the quarter. The legal entity remains Novo Nordisk A/S and the ADR remains NVO. More substantively, the quarter is the first in which management reports progress against the three commitments set at the September Capital Markets Day: grow and diversify the pipeline, drive sustainable growth, deliver attractive returns.

"Back in September, at our Capital Markets Day, we set out our 2030 ambition to deliver mid-single-digit compounded annual sales growth in line with our industry peers from 2026 to 2030... From this quarter onwards, we will hold ourselves accountable and report progress against each of them." — Mike Doustdar, President and CEO

Assessment: Reporting against a stated ambition every quarter is a governance improvement and it is the right response to a Capital Markets Day that cost the shares 8% on the day. The ambition itself is the issue: mid-single-digit growth "in line with industry peers" is an explicit abandonment of the premium-growth identity the multiple was once struck against, measured from a 2026 base that the company is guiding to flat. The framework now makes 2027 the test of whether a flat 2026 is the trough of a recovery or the first year of the new run rate, and February is when that gets answered.

Guidance & Outlook

Two features separate this revision from August's. The first is that the kroner-versus-constant-currency wedge has closed entirely: in February reported sales growth was guided three points below the constant-currency figure and operating profit five points below, and both are now in line. That is worth roughly DKK 6bn of operating profit relative to the February assumption and none of it is operational. The second is the cash guidance. Free cash flow has risen DKK 25bn since February, from DKK 35-45bn to DKK 60-70bn, while capital expenditure guidance has been cut for the first time this year with a statement that it keeps declining in the coming years. On the DKK 65bn midpoint, against a market value near DKK 1.2 trillion, Novo is now guiding to a free cash flow yield above 5% at a company whose capital expenditure has peaked.

Implied fourth-quarter ramp: This is the arithmetic the call did not finish. Full-year 2025 adjusted sales were DKK 306,415M and full-year 2025 adjusted operating profit DKK 125,009M, both after stripping the DKK 2,649M 340B reversal. Nine months of 2026 delivered DKK 232,645M of sales and DKK 100,902M of operating profit at constant exchange rates. Against the guided -2% to +2%, the fourth quarter must therefore produce DKK 67,642M to DKK 79,898M of sales, against DKK 79,144M a year ago, which is -14.5% to +1.0% with a midpoint near -6.8%. The DKK 12.3bn width of that range is the figure one analyst raised on the call, and management confirmed the breadth was customary for the quarter.

The same arithmetic on the profit line is the part nobody ran. The guide implies fourth-quarter adjusted operating profit of DKK 21,607M to DKK 26,607M against DKK 31,736M a year ago, a decline of 16% to 32% at constant currency, and an implied fourth-quarter adjusted operating margin of roughly 32% to 33%. Nine months printed 43.0% and the fourth quarter of 2025 printed 40.1%. The two items management named, a DKK 3bn US gross-to-net benefit in the fourth quarter of 2025 worth 3.8 points of the sales base and Canadian loss of exclusivity weighted to the fourth quarter, do not account for a 700 to 800 basis point margin reset. The guided investment step-up does, and that is the reading the outlook language supports.

"In terms of implied growth, it is important to note that while we are growing 2% year to date and we have a midpoint of zero, we do have a tough comparator in the fourth quarter due to U.S. gross-to-net last year of DKK 3 billion in the fourth quarter. LOE in mainly Canada, Emil spoke to also having a bigger impact in the fourth quarter compared to the first nine months." — Karsten Munk Knudsen, CFO

Street at: Consensus entering the print sat against a guide of -6% to 0% on adjusted operating profit, with the polled full-year figure near -3%. The mechanical revision upward is four points at the floor and two at the ceiling. The place the Street is most likely to be wrong is the same place as last quarter, in the opposite direction: carrying the 43.0% nine-month adjusted operating margin into the fourth quarter contradicts a guide the company has just set, and carrying the implied 32% to 33% forward into 2027 would extrapolate a quarter that contains launch preparation for a product that launches once.

Guidance style: Conservative in level, credible in shape, and now with a three-quarter track record. Each of the three raises has upgraded delivered results rather than expected ones and none has widened the band. The implied fourth quarter is almost certainly not a forecast: a company that has beaten its own floor three times running has not suddenly guided to a 24% profit decline it expects to hit at the midpoint. The useful inference is not that the fourth quarter will be bad but that the guide is reserving room for spending that management intends to do, which is a different and better reason for a low number.

Analyst Q&A Highlights

Whether 2027 Can Be a Growth Year

The dominant topic of the call, raised in the first question and returned to twice more because the first answer did not settle it. The question was whether a positive revenue growth number could appear in the February range, given what the pill is doing internationally and what the Ozempic pill relaunch is doing in the US. Management declined to guide but went further than usual, offering three positives and three negatives and naming each. A follow-up pressed specifically on which base to use, the second-half exit rate or the full-year midpoint of zero, and the answer chose neither explicitly while leaning on the latter.

Q: "I realize you are not going to provide any official guidance ahead of a CFO change, but a frequent question we get from investors is whether Novo Nordisk can return to revenue growth in 2027. I know there are many moving parts, but just wanted to kick the tires with you on your confidence that a positive growth number could feature in any guidance range you provide in February, given what you are seeing across IO markets with the pill and post the Ozempic pill launch."
— Peter Verdult, BNP Paribas

A: "Let me give you three plus and three minus. The pluses for us next year is the continued Wegovy pill uptake in U.S. and IO. I don't foresee why should that completely change, and how well we've done both in U.S. and in IO does not change just because January comes after December. The other plus is we have seen a good uptake in U.S. Bridge Program. That program started mid this year, so you need to annualize it when you make your calculation for next year. Then the third positive element, I would say, is the two launches I just spoke about. CagriSema, Frehemgo are two launches where we plan to introduce CagriSema in U.S. Frehemgo in both sides of the Atlantic, and hopefully both of those will prove to be fantastic launches. On the negative side, I would say we've talked about the LOE this year in international operations and the early LOE markets. We have seen some of that already, more of it in Q3 than we saw in Q2. Next year, I would say annualize that and see how that goes. Then the continued headwind that you currently see in China, -2% that we just showed, is not going to go away just because Christmas turns into, again, a new year. In addition, in China, we have loss of exclusivity next year, which you need to take into consideration. Then last, maybe but not least, you see some favorable gross to net in 2026 that we should maybe under normal circumstances not expect to the same degree next year."
— Mike Doustdar, President and CEO

Assessment: The most useful 2027 disclosure of the year, and it still does not answer the question. Two of the three positives are annualisations of 2026 events rather than new growth, and the third is two launches of which one has no published pricing. Two of the three negatives are dated and quantifiable by the company and were not quantified. The repeated insistence that the full-year midpoint of zero rather than the second-half exit rate is "basically how we're going to look at this going forward" is the closest thing to a 2027 anchor on offer, and it points to flat rather than growth.

How Much of the US Pill's Growth Is the Medicare Bridge

A recurring line of questioning, pressed by one analyst with their own prescription data suggesting the bulk of the growth was Medicare and that it was sequentially slowing, and then sharpened by another into the direct question of whether the franchise would have grown at all without the programme. Management answered both without deflection, and the second answer is the one that matters.

Q: "Question is just a follow-up on your commentary, Jamey, on the Bridge contribution to the franchise. Do I understand correctly that without Bridge, you wouldn't have grown the GLP-1 franchise? What does that then mean as Bridge starts to annualize?"
— Michael Leuchten, Jefferies

A: "Without the Bridge contribution, there is less growth than the 20% sequential growth that we talked about. Bridge is definitely creating an inflection in the category, and without Bridge, the AOM category, not just Novo, but the category, looks relatively flat in the May to October timeframe, reflecting the seasonality."
— Jamey Millar, EVP US Operations

Assessment: The exchange that should set the rating. Management conceded that the entire US anti-obesity category, not just Novo's share of it, is relatively flat from May to October once a government demonstration programme is removed, and attributed the residual to seasonality rather than demand. That is a candid answer and a damaging one, because it means the single piece of evidence that would justify an upgrade rests on a programme with a 2027 expiry and no committed successor.

The Width of the Implied Fourth Quarter

One analyst did the arithmetic on the raised range and put the implied fourth-quarter sales swing at DKK 12bn, asking what the key factors were, and in the same question asked whether 2026's favourable gross-to-net was an unwind or a new base. Management addressed the width and the two named headwinds and did not address the gross-to-net base question, nor the implication of the same arithmetic for the profit line.

Q: "On the upgraded guidance range for 2026, the implied range for Q4 is super wide. I think it's a DKK 12 billion swing. So, what are the key factors we need to consider there? As we look into next year, with the gross-to-net quite high this year, how should we treat that as we're thinking for 2027? Is that an unwind, or is that a new base from which sales need to grow from?"
— James Quigley, Goldman Sachs

A: "Specifically, to your question on implied growth and guidance ranges, I will just say, as to the guidance ranges, the breadth we have here at Q3 is completely customary at this point in time. The reason why we have this breadth is that we are navigating a rapidly growing category with a certain degree of volatility. That is why we keep it a little bit wider compared to the heydays when it was pure insulin and extremely linear."
— Karsten Munk Knudsen, CFO

Assessment: The DKK 12bn figure is correct and independently reproducible from the company's own bases, which is the cross-check that the implied fourth quarter in our Guidance section is calculated on the right footing. Attributing the width to category volatility is reasonable as far as it goes. What went unaddressed is that the same guide implies a fourth-quarter operating margin roughly ten points below the nine-month run rate, and that the gross-to-net question, which is the single largest swing factor in a 2027 model, was asked directly and not answered.

Where Wegovy HD's Volume Is Actually Coming From

A precise question on the composition of high-dose volume, asking whether it was titration from 2.4 mg, switching from the competitor, or new starts, inside and outside the US. The answer was the most specific disclosure the company has made on this product and it closes the efficacy-parity argument rather than supporting it.

Q: "Secondly, on Wegovy HD, you helpfully told us that it's 5% of total Wegovy scripts in the U.S., but I wonder if you could give us any more color, both within and outside the U.S., on where that's coming from. Are these predominantly titrations up from Wegovy, switches from tirzepatide, or patients starting a fresh on that therapy?"
— Simon Baker, Rothschild & Co Redburn

A: "If you look into the injectable business, both Lilly's and ours, about 15% of the TRxs are in the highest dose. There is still opportunity to move Wegovy HD further. 80%, your specific question, 80% of Wegovy HD is titration from 2.4 mg. Those 20,000 scripts a week are scripts that otherwise would have been lost to the Wegovy franchise."
— Jamey Millar, EVP US Operations

Assessment: Asked and answered completely, and the answer breaks a thesis pillar. A product positioned as restoring efficacy parity to win back share is, seven months in, 80% existing patients moving up a dose, at 5% of volume in a category where 15% of prescriptions sit at the top dose. Management's own framing of it as retention is the right one. The high-dose strategy is defending the base, not recapturing the share lost over the preceding two years.

US Price Dynamics Into 2027

Asked twice in different forms: once on whether lower 340B rebates were flowing through to better realised Ozempic prices and whether the Inflation Reduction Act remained a 2027 headwind, and once on the main building blocks for 2027 pricing. Neither 340B nor the Inflation Reduction Act was addressed. What management did was hold its annual price-erosion framework unchanged while acknowledging the quarter had run better than it, and then, twenty minutes later in answer to the second version of the question, volunteer an unprompted clarification on the Medicare negotiated price that it had skipped the first time.

Q: "Maybe you could talk about the underlying price dynamics this quarter throughout this year, whether there's any impact from lower 340B rebates flowing through to better prices, and how you're thinking about that into next year. I noticed you didn't mention IRA next year. I know we talked about that last quarter, but is that still a headwind in terms of price, or are there price benefits that offset that next year?"
— Richard Vosser, JPMorgan

A: "So, as we've guided before, suggested the 10%-15% price erosion on an annual basis is the way to think about it. There's so much fluctuation, variability quarter to quarter. Obviously, in the quarter, we saw significantly better range than the 10%-15%, but year to date and over a 12-month period, we still feel 10%-15% is reasonable. The payer pressure on net prices in the Type 2 diabetes category remain and will continue. So, that's our best judgment there."
— Jamey Millar, EVP US Operations

Assessment: Holding a 10% to 15% annual erosion framework through a quarter that ran "significantly better" is conservative, and conservatism on price is consistent with how this team has guided all year. The two specific items asked about were not answered: whether lower 340B rebates are flowing through to realised price, which is the mechanism behind the DKK 26.8bn provision reversal still distorting the nine-month figures, and whether the Inflation Reduction Act remains a 2027 price headwind. The separate clarification that the Medicare negotiated price carries no incremental drag, offered later as a cleanup, is the most consequential forward statement in the Q&A and is entirely unquantified.

The UK Pill Run Rate After the Launch Bolus

A direct request for an updated weekly pack number against the figure given at the September Capital Markets Day, following management's own use of the word normalising in the prepared remarks. The answer confirmed a decline and paired it with the cannibalisation evidence that is the more important half of the UK case.

Q: "For Emil, you commented on U.K. normalizing. I'm just after an updated pack number relative to the 65,000 per week you gave at the CMD."
— Sachin Jain, Bank of America

A: "In terms of how we fare versus what we shared at the Capital Markets Day, we back then talked about 65,000 packs weekly sales. Now we are probably around 60. So despite a competitor launch, super strong, and also with the seasonality at the moment being a bit low... What you should also take note of... is of course that this is not cannibalizing our injectable business. So that is perhaps what I am most pleased about. This is really adding to our overall market share, so we are still faring more than 10 percentage points higher than we did prior to the launch overall."
— Emil Kongshøj Larsen, EVP International Operations

Assessment: Answered honestly and without hedging on the number, which is a credit to the disclosure standard on this call. The 65,000 to 60,000 move is small in isolation and matters because the UK was the strongest datapoint in the entire bull case three months ago, offered then as proof that an oral GLP-1 expands a national treated population rather than redistributing it. The expansion claim survives, with Novo's UK obesity share still more than ten points above pre-launch. The growth claim does not.

Whether Commercial Payers Will Ever Step In

A question about the strategic implication of the Bridge dependence: if a government programme is what inflects the category, what gets private employers and insurers to fund obesity treatment on the clinical evidence. Management's answer was candid about the mechanism and named employers publicly.

Q: "My question is just kind of going back to the comment about the sequential growth from March basically being flat and the contribution of the Medicare Bridge program being the main accelerator. That speaks to, I think, to some degree, a cautionary tale for payers potentially lowering the price or helping to lower the price of treatment. I guess the big question is, how do you get commercial pay to really step in and start to reveal the benefits, the medical benefits that we all know GLP-1s actually have, given several appear to have pulled back from supporting the obesity opportunity?"
— Seamus Fernandez, Guggenheim Securities

A: "It's a simple question with a difficult answer, but the reticence on behalf of the downstream payers, employers, government, private payers, is increasingly about the volume concern side of the equation. Price keeps coming down, net prices. Competition's working in that sense. Our list prices will also come down 1/1/2027, as previously announced. But how payers control the cost trend that they see, which is the price times volume equation, is the challenge... But you're right, whether it's Pepsi, Starbucks, other large employers, when they see the cost trend, they move against, despite the clinical and economic benefit long-term of medical cost offsets that have been demonstrated in the market."
— Jamey Millar, EVP US Operations

Assessment: The clearest statement of the structural problem anyone has made on one of these calls. Price is no longer the binding constraint on access; aggregate cost is, and cutting price raises volume and therefore aggregate cost. That is why the January list-price reset cannot be modelled as a simple price-times-volume trade, and it is why a 50% list-price cut can coexist with payers tightening rather than loosening. It also reframes the Bridge dependence as a feature of the category rather than a Novo-specific weakness, which is accurate and not reassuring.

The Tolerability Bar for the Triple-Agonist Readouts

A question about managing expectations for the phase 1/2 readouts on the two tri-agonists in the first half of 2027, specifically on adverse events after earlier phase trials in the class produced elevated rates. The answer drew a distinction between phase 1 capture methodology and phase 2 results and set an explicit bar.

Q: "I am not expecting you to give some kind of indication where you see the weight loss. I would more like to get you to get some expectations of how we should view the adverse events profile going on to this, because there has been some noise when Novo Nordisk come out with the phase II results and high level of adverse events. How have the trials on the triagonist been set up with respect to this, just to control expectations?"
— Martin Parkhøi, SEB

A: "I just want to clarify where we typically see adverse events rates being captured in a very rigorous way is in phase I, because we follow the patients very, very closely there... Those are a little bit technical, but also a little bit artificial. What we will see readouts of is proper phase II trials, and here we actually expect to see the expected adverse event profile and tolerability profile of these two drugs... our aspiration is to have adverse events in line with what we've seen with Wegovy and with other GLP-1 incretin-based therapies. For the triple, we potentially expect to see either in line and potentially even a more attractive safety profile and tolerability profile, because the GIP component will come to its own right here."
— Martin Holst Lange, EVP R&D and CSO

Assessment: A clear bar set in public a quarter ahead of the data, which is the right way to handle a readout the market has already been burned on. Tolerability in line with Wegovy is the stated aspiration for both molecules and better than Wegovy for the triple. It is also a reminder of where this pipeline sits: the next two obesity readouts are phase 1/2 datasets whose primary job is to not disappoint, roughly three years before either could reach a market.

What They're NOT Saying

1. Any quantification of the January 2027 list-price reset, for the third consecutive quarter. A roughly 50% cut to Wegovy's wholesale acquisition cost and roughly 35% to Ozempic's, effective 1 January 2027 on a known date, still gets one paragraph and one sentence of financial effect: it "is expected to impact Novo's cash flow in 2027." No net price impact, no volume offset, no gross-to-net mechanics, no Part D or Medicaid bridge. It drew no direct question again.
2. The fourth-quarter operating-profit implication of the guide the company just raised. The implied range on sales was computed on the call and confirmed. The same arithmetic on the profit line gives a 16% to 32% constant-currency decline and a roughly 32% to 33% adjusted operating margin against 43.0% for the nine months. Management did not volunteer it and no analyst ran it.
3. Whether 2026's favourable gross-to-net is an unwind or a new base. Asked directly, in the same breath as the fourth-quarter question, and not answered. The chief executive separately listed it as one of three 2027 negatives without sizing it. It is the largest single unknown in a 2027 revenue model.
4. What happens to the Medicare Bridge cohort after 2027. Management described the political dynamics thoughtfully and committed to nothing, because it has nothing to commit to. Roughly 60,000 weekly prescriptions and the entire inflection in the US category's growth rate depend on a programme whose continuation is a decision somebody else makes.
5. Persistence, stay time and refill rates on the pill. Flagged as missing in May, in August, and missing again. Eight million cumulative prescriptions is a flow number. Nothing published lets an outsider convert it to a durable patient base, and the chief executive's comment to reporters that the script curve has flattened makes the distinction more urgent rather than less.
6. The Wegovy pill's gross margin. Now 21% of obesity sales and the largest single driver of consolidated gross-margin trajectory. Unasked for a third quarter and undisclosed.
7. The IQVIA capture rate, asked again and still unquantified. Management maintains that external providers understate pill prescriptions because its partner ecosystem is broader than the competitor's and those partners do not report. That is a credible explanation and it is also unfalsifiable without a number, and it is the only thing standing between the reported script deceleration and a demand problem.
8. CagriSema pricing and access, one quarter before a US decision. The commercial frame advanced from nothing to a segmentation hypothesis about low doses and perimenopausal women. Price, formulary strategy, cannibalisation of a three-product Wegovy bag and the interaction with a list-price reset landing in the same month all remain unaddressed.
9. The segment attribution of the DKK 4.1bn manufacturing impairment. The ziltivekimab DKK 4.6bn is named and attributable. The manufacturing charge is not split, and it lands in the same quarter the company pushed a US product launch on manufacturing facility remediation. The two are not stated to be related and the disclosure does not let a reader rule it out.
10. Why free cash flow guidance of DKK 60-70bn follows nine months of DKK 83.8bn. The implied fourth quarter consumes DKK 13.8bn to DKK 23.8bn of cash. The raise was presented as good news, the arithmetic consequence was not presented at all, and no analyst asked. This is the second consecutive quarter in which the free cash flow guide implies a cash-consuming stub period.

Market Reaction

• Pre-print setup: The ADR closed at $40.19 on 3 November, down 21.0% year to date against the S&P 500's +10.6%, down 16.7% over the trailing twelve months, but up 7.1% over the trailing thirty days from $37.54 on 5 October. The 52-week closing range entering the print was $35.29 to $63.98. The stock arrived having already recovered part of the 8% single-session fall that followed the September Capital Markets Day.
• Reaction session (4 November, before-the-open reporter): Opened at $42.45, a 5.6% gap up, traded a range of $42.12 to $43.24, and closed at $42.18, up 5.0% or $1.99. The S&P 500 rose 1.6% the same session, so the relative move was roughly +3.4 points. The Copenhagen line was quoted up as much as 6.6% early and up 1.9% by mid-session.
• Volume: 26.0 million ADRs against a 12.1 million thirty-day average, or 2.2x normal.
• Next-day session (5 November): Closed at $40.30, down 4.5%. The S&P 500 fell 4.4% the same session and the closest category comparable fell 3.8%, so the decline tracked a market-wide risk-off day rather than reversing the print. Two-session net from the pre-print close: +0.3%.

The intraday path on the reaction day repeats a pattern this stock has now shown twice. It gapped 5.6% on the headline, traded as high as $43.24, and closed at $42.18, near the bottom of its range and below the open, while the index rose 1.6%. In August the same shape ended in a 6.0% decline. This time it ended in a 5.0% gain, which is the difference three guidance raises make, but the fade is the same. The timing does not tie the fade to the call: Copenhagen had already eased to +1.9% by late morning local time, before the 13:00 CET call began, and the ADR's regular session opened after the call had ended.

What the market bought on the print is straightforward: a beat on all three polled lines, the third raise of the year, a DKK 15bn free cash flow upgrade and a capital expenditure cut. What weighed on it through the session, on our reading, is the Bridge disclosure. The US obesity reacceleration, which was the single most anticipated line in the release, was explained during the Q&A as largely a government demonstration programme sitting on top of a relatively flat category, and that explanation came in an answer to a question rather than in the release or the prepared remarks. The sequencing is identical to August, when the 22% decline in US injectable Wegovy sat in a regional appendix and the second-half bridge arrived thirty minutes into the call.

Positioning context. A stock up 7.1% over thirty days into a print is carrying more expectation than one that has just fallen 8.8% on a failed trial, which is the setup August had. That makes a 5.0% gain on an 8% revenue beat and a guidance raise of four points at the floor a modest response rather than a generous one, and it is the clearest evidence of where the credibility discount still sits. Over twelve months the ADR is down 16.7%, and across the two sessions around this print it is net unchanged. The market has now spent a year marking this business down while the composition of the bull case has been almost entirely rebuilt, from injectable share recovery to oral scale plus a reimbursement programme.

Street Perspective

Debate: Is the US Obesity Reacceleration a Turn or a Subsidy?

Bull view: US obesity grew 20% at constant currency against a market decelerating to 71%, the gap narrowed from 83 points to 51, injectable Wegovy's decline halved to 13% with realised price per unit up sequentially for the first time we can measure, and combined US Wegovy grew 21%. The composition is beside the point: a reimbursed channel at better pricing than cash-pay is a better business than the self-pay mix it supplements, and Bridge demonstrates the thing the bull case has always claimed, that treated population expands when access does.

Bear view: Management said the whole category is relatively flat ex-Bridge from May to October. The programme has been live four months, contributes roughly a tenth of franchise volume, and is a demonstration project with a 2027 end date and no committed successor. Meanwhile the franchise's new-to-brand share fell for a second consecutive disclosure and international GLP-1 volume share dropped four points. A gap closed by somebody else's reimbursement decision is not share won.

Our take: The bear framing is the better description of this quarter and the bull framing is the better description of the opportunity. We named this gap's narrowing as the condition for moving toward Outperform and it narrowed, so the discipline is to say plainly why that is not enough: the condition was meant to be evidence that Novo competes, and what the quarter shows is that Novo participates when a payer opens a channel. The test is now the first quarter of 2027, when Bridge annualises into the base and stops flattering the growth rate. If US obesity still grows then, the condition has genuinely been met.

Debate: Does the Guidance Raise Mean the Earnings Decline Is Over?

Bull view: Three raises in nine months, the floor up 11 points from February, the currency drag eliminated, free cash flow guidance up DKK 25bn since February and capital expenditure cut with a statement that it keeps falling. Nine-month adjusted operating profit is up 8% at constant currency with margins up 200 basis points. A company guiding to flat sales and generating a 5% free cash flow yield at 11.7x earnings is being priced for a decline that its own numbers have stopped describing.

Bear view: Adjusted earnings per ADR fell 12% in the quarter and 3% over nine months, and the operating-profit growth that reads as an inflection is an artefact of a prior-year base carrying DKK 9bn of restructuring that the adjusted definition does not strip. Underlying operating profit grew roughly 3%. The guide's own arithmetic implies a fourth-quarter margin ten points below the nine-month run rate, and 2027 opens with a 50% list-price cut on the flagship product that nobody has quantified across three quarters.

Our take: The bear framing wins on the current year and the bull framing has the better claim on the cash. Both sides are arguing about the wrong line: the operating-profit guide is unusable as an earnings signal because its base and the earnings base treat the 2025 restructuring differently, which is why we have rebuilt the estimate from the nine-month actual rather than flexing the prior-year figure. The answer that emerges is that 2026 adjusted earnings fall roughly 10%, and that the cash statement is genuinely better than the earnings statement because capital expenditure has peaked. That combination supports the current multiple and does not expand it.

Debate: Is the Pipeline Now Good Enough to Underwrite 2028?

Bull view: The specific pipeline break of the second quarter has been repaired. CagriSema beat tirzepatide 5 mg on weight loss while matching it on glycaemic control at a 1.0/1.0 mg dose, delivered 21% weight loss in obesity at that same low dose, and has a US decision inside this quarter with a launch framed for early 2027. Etavopivat, which met both co-primary endpoints in phase 3 in April, is due to file in the US and EU this quarter. Frehemgo has a positive EU opinion. Five phase 3 trials started on zenagamtide alone, with ten phase 3 programmes running and seven first-human-dose studies by the end of October. That is the activity level the Capital Markets Day promised.

Bear view: In six months a Data Monitoring Committee has recommended terminating both remaining ziltivekimab heart-failure trials, monlunabant has been written off, impaired DKK 15.0bn of pipeline and manufacturing assets, and pushed a US haemophilia launch on its own manufacturing remediation. The next two obesity readouts are phase 1/2 datasets in 2027 whose stated aspiration is tolerability merely in line with a thirteen-year-old molecule. Nothing in the pipeline reaches a market before the semaglutide exclusivity cliff and the 2027 price reset have both landed.

Our take: The bull case has the better of this one again, which is a change from August when we scored this pillar as challenged. The distinction that matters is whether the assets that remain can differentiate, and REIMAGINE 5 is the first head-to-head in our coverage in which a Novo asset beat the category leader on the endpoint that sells the category. The qualification is timing, not quality: CagriSema is a 2027 and 2028 revenue story that launches into a list-price reset with no published pricing, and everything behind it is a 2029 story at the earliest. The pipeline underwrites 2028 better than it did three months ago and does nothing for 2027.

Model Update & Valuation Framework

Changes to the assumptions carried from August, driven by the guidance revision, the nine-month actuals and a correction to the earnings build.

Valuation framework. Nine-month adjusted diluted EPS is DKK 18.60. The fourth quarter's adjusted operating profit implied by the guide is DKK 21,607M to DKK 26,607M. Fourth-quarter financial items are the DKK 1.6bn full-year guided loss less the DKK 791M nine-month gain, or a DKK 2,391M loss. Adding back the roughly DKK 1,654M of quarterly amortisation on intangibles that adjusted net profit excludes, taxing at the 22% guide midpoint and dividing by 4,420 million diluted shares gives fourth-quarter adjusted EPS of DKK 3.68 to DKK 4.57 and full-year 2026 adjusted EPS of DKK 22.28 to DKK 23.17. Running the identical build backwards on the fourth quarter of 2025 reproduces DKK 6.30 against an actual DKK 6.43, a 2% residual, which is the margin of error on the method.

We carry a range of DKK 22.3 to DKK 24.4 with a working number of DKK 23.2. The low end is the guide taken literally. The working number is the top of the guide, which is where a management team that has raised three times on delivered results should be assumed to land. The high end assumes a fourth quarter at normal seasonal margins of roughly 42%, which produces DKK 24.25 and requires the promised investment step-up not to arrive, so we treat it as the upside case rather than the base. At the company's stated spot rate of 671 kroner per 100 dollars, DKK 23.2 is approximately $3.46 per ADR, with the range spanning $3.32 to $3.64.

Against the $42.18 reaction close the ADR trades at approximately 12.2x our 2026 midpoint, and against the $40.30 close on 5 November at approximately 11.7x. That compares with 12.2x in August and 13.9x in May. The multiple has not moved since August and the dollar estimate is 5% lower, three points of which is a weaker krone and two points the corrected build.

Fair value range: $42 to $52, midpoint $47. The range applies 12x to 15x to the working estimate. From the $42.18 reaction close the low end implies -0.4%, the midpoint +11.4% and the high end +23.3%; from the $40.30 close the same points imply +4.2%, +16.6% and +29.0%. We have held the multiple range rather than raising it, despite a third guidance raise and a genuine cash-flow inflection, for one reason: the 2027 earnings bridge across the January list-price reset is now in its third quarter of being asked for and not delivered, and it will be delivered in February by an incoming chief financial officer. A multiple above 15x requires knowing what 2027 earns. Nobody outside the company does, and the evidence of this quarter is that nobody inside it will say before February.

Thesis Scorecard Post-Earnings

The pillars below are the standing thesis established at initiation in May, graded against this quarter's print and call. Bull #4 no longer names ziltivekimab, whose heart-failure trials have been closed or are completing; otherwise only the status and the notes move.

Overall: Strengthened on the pipeline, weakened on the share argument, and unchanged in net. Two tags moved in opposite directions: the pipeline pillar recovered to on track because the asset that broke it in August repaired its own endpoint in a head-to-head against the category leader, and the efficacy-parity pillar broke because seven months of data now show the high dose defending the base rather than recapturing share. The two bear pillars that decide the revenue line were confirmed again, with Bear #1 failing to strengthen for the first time since initiation. The quarter's achievements, a beat on every polled line, a third guidance raise, a DKK 15bn cash-flow upgrade, the first narrowing of the US obesity gap and a repaired lead pipeline asset, are real. They sit against a US reacceleration that management describes as largely driven by a government programme that expires in 2027, a 2027 price reset unquantified for a third quarter, and a 2027 guide deferred to February under a new chief financial officer.

Action: Hold. At approximately 12.2x our 2026 adjusted earnings estimate on the reaction close, unchanged from August, and 11.7x after the 5 November market-wide sell-off, the ADR is cheaper than it was in May, the guidance floor has moved 11 points since February, free cash flow guidance has risen DKK 25bn since February and capital expenditure has peaked. That rules out Underperform even though one of the two Underperform conditions set at initiation, a resumption of international share loss, was met this quarter: a 54% international GLP-1 volume share against roughly 58% in August is a four-point loss on a consistent basis, and the pill is emphatically not stalling, which was the other condition. On the other side, the Outperform condition we have named for two quarters, a narrowing of the gap between US obesity revenue growth and US market volume growth, was met in form and undermined in substance by management's own account of how. The second Outperform condition, a quantified 2027 price-and-volume bridge, was not met: the September Capital Markets Day produced a 2030 revenue ambition instead, and February now carries it. We would revisit toward Outperform if the first quarter of 2027 shows US obesity growing with Bridge in the comparative base, or if the February guide quantifies the list-price reset's net effect and still describes growth. We would revisit toward Underperform if the international share decline extends for a second quarter while EUCAN decelerates, or if the February guide resets 2027 earnings materially below the DKK 22-23 this year is tracking.